| MeSH term | MeSH ID | Detail |
|---|---|---|
| Stomach Ulcer | D013276 | 75 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Parkinson Disease | D010300 | 53 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lin KJ et al. | Safety of macrolides during pregnancy. | 2013 | Am. J. Obstet. Gynecol. | pmid:23254249 |
| Gascón A et al. | Catheter salvage in a patient on hemodialysis with a catheter-related bacteremia by Pseudomonas aeruginosa. Usefulness of clarithromycin. | 2000 Nov-Dec | Am. J. Nephrol. | pmid:11146320 |
| Gokturk HS et al. | Does long-term aspirin use have any effect on Helicobacter pylori eradication? | 2011 | Am. J. Med. Sci. | pmid:21642817 |
| Brener ZZ et al. | Rhabdomyolysis following clarithromycin monotherapy. | 2009 | Am. J. Med. Sci. | pmid:19474653 |
| Songür Y et al. | Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. | 2009 | Am. J. Med. Sci. | pmid:19474657 |
| Demir M et al. | Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. | 2009 | Am. J. Med. Sci. | pmid:19884816 |
| Butt AA | Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. | 1998 | Am. J. Med. Sci. | pmid:9427575 |
| Baciewicz AM et al. | Update on rifampin and rifabutin drug interactions. | 2008 | Am. J. Med. Sci. | pmid:18277121 |
| Santos MA et al. | Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. | 2017 | Am. J. Med. | pmid:27984010 |
| Curtis LH et al. | Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. | 2003 | Am. J. Med. | pmid:12586234 |
| Nayyar E and Taimur S | Sporotrichoid lesions: an age-old conundrum. | 2015 | Am. J. Med. | pmid:26021809 |
| Jaber BL et al. | The serotonin syndrome complicating co-prescription of paroxetine and clarithromycin. | 2006 | Am. J. Med. | pmid:16564762 |
| Cicconi V et al. | Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. | 2001 | Am. J. Med. | pmid:11501549 |
| Siddiqui J | Immunomodulatory effects of macrolides: implications for practicing clinicians. | 2004 | Am. J. Med. | pmid:15586561 |
| Tamaoki J et al. | Clinical implications of the immunomodulatory effects of macrolides. | 2004 | Am. J. Med. | pmid:15586558 |
| Abisheganaden JA et al. | Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. | 2000 | Am. J. Med. | pmid:10781777 |
| Gotfried MH | Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program. | 2001 | Am. J. Med. | pmid:11755440 |
| Sherman PM | Appropriate strategies for testing and treating Helicobacter pylori in children: when and how? | 2004 | Am. J. Med. | pmid:15478850 |
| Sokol W | Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. | 2001 | Am. J. Med. | pmid:11755439 |
| Pfaller MA et al. | Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. | 2001 | Am. J. Med. | pmid:11755437 |
| Lee KL et al. | QT prolongation and Torsades de Pointes associated with clarithromycin. | 1998 | Am. J. Med. | pmid:9576415 |
| Hunt RH | Eradication of Helicobacter pylori infection. | 1996 | Am. J. Med. | pmid:8644782 |
| Stasi R et al. | Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. | 2005 | Am. J. Med. | pmid:15808140 |
| Steinman MA and Steinman TI | Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. | 1996 | Am. J. Kidney Dis. | pmid:8546130 |
| Wang YL et al. | Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. | 2001 | Am. J. Kidney Dis. | pmid:11431188 |
| Mendu ML and Waikar SS | Drug-drug interactions and acute kidney injury: caveat prescriptor. | 2014 | Am. J. Kidney Dis. | pmid:24820318 |
| Okada S et al. | Angiocentric immunoproliferative lesions of the lung associated with diffuse renal involvement. | 2002 | Am. J. Kidney Dis. | pmid:11877592 |
| Mak SK et al. | Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure. | 2002 | Am. J. Kidney Dis. | pmid:12200810 |
| Sekkarie MA | Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. | 1997 | Am. J. Kidney Dis. | pmid:9292575 |
| Keenan N et al. | Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. | 2005 | Am. J. Kidney Dis. | pmid:15861339 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| Gaur S et al. | Bronchus-associated lymphoid tissue lymphoma arising in a patient with bronchiectasis and chronic Mycobacterium avium infection. | 2004 | Am. J. Hematol. | pmid:15307101 |
| Rostami N et al. | Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. | 2008 | Am. J. Hematol. | pmid:18183613 |
| Ghosh N et al. | Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. | 2014 | Am. J. Hematol. | pmid:24723438 |
| Gay F et al. | Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. | 2010 | Am. J. Hematol. | pmid:20645430 |
| Mirabile A et al. | MALT lymphoma and Kaposi sarcoma in an HIV-negative patient. | 2010 | Am. J. Hematol. | pmid:20721890 |
| Adamek RJ et al. | Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. | 1995 | Am. J. Gastroenterol. | pmid:7801936 |
| Jaup BH and Norrby A | Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7771426 |
| Gisbert JP et al. | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | 2005 | Am. J. Gastroenterol. | pmid:16128936 |
| Isomoto H et al. | Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. | 2005 | Am. J. Gastroenterol. | pmid:16086706 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Laine L et al. | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. | 2003 | Am. J. Gastroenterol. | pmid:12650788 |
| Schaeverbeke T et al. | Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. | 2005 | Am. J. Gastroenterol. | pmid:16393213 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Chey WD and Wong BC | American College of Gastroenterology guideline on the management of Helicobacter pylori infection. | 2007 | Am. J. Gastroenterol. | pmid:17608775 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Peterson WL et al. | Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. | 1993 | Am. J. Gastroenterol. | pmid:8237933 |
| Nista EC et al. | Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. | 2006 | Am. J. Gastroenterol. | pmid:16968503 |
| van Zanten SV and Thompson K | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? | 2006 | Am. J. Gastroenterol. | pmid:16863548 |
| Froehlich F et al. | Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. | 2001 | Am. J. Gastroenterol. | pmid:11513170 |
| Rokkas T et al. | Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. | 2006 | Am. J. Gastroenterol. | pmid:16928256 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Coelho LG et al. | Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. | 2000 | Am. J. Gastroenterol. | pmid:10710099 |
| Pilotto A et al. | In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. | 2000 | Am. J. Gastroenterol. | pmid:10710100 |
| Hansen JM et al. | Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. | 2008 | Am. J. Gastroenterol. | pmid:18445098 |
| Vakil N | H. pylori treatment: new wine in old bottles? | 2009 | Am. J. Gastroenterol. | pmid:19098845 |
| Rokkas T et al. | Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. | 2009 | Am. J. Gastroenterol. | pmid:19098844 |
| Lazzaroni M et al. | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. | 1997 | Am. J. Gastroenterol. | pmid:9128316 |
| Sapone A et al. | The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. | 2003 | Am. J. Gastroenterol. | pmid:12809821 |
| Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Levy M et al. | Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. | 2002 | Am. J. Gastroenterol. | pmid:11866264 |
| Christopher K et al. | Clarithromycin use preceding fulminant hepatic failure. | 2002 | Am. J. Gastroenterol. | pmid:11866297 |
| Gisbert JP et al. | Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. | 2006 | Am. J. Gastroenterol. | pmid:16454825 |
| Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Lamouliatte H et al. | Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. | 1998 | Am. J. Gastroenterol. | pmid:9732938 |
| Hsu PI et al. | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. | 2005 | Am. J. Gastroenterol. | pmid:16279889 |
| Vakil N | Helicobacter pylori: factors affecting eradication and recurrence. | 2005 | Am. J. Gastroenterol. | pmid:16279890 |
| Sullivan B et al. | Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:12385435 |
| Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
| Gisbert JP et al. | Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. | 2008 | Am. J. Gastroenterol. | pmid:17764498 |
| Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
| Dohil R et al. | Effective 2-wk therapy for Helicobacter pylori disease in children. | 1997 | Am. J. Gastroenterol. | pmid:9040199 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Chey WD et al. | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. | 1997 | Am. J. Gastroenterol. | pmid:9317068 |
| Gatta L et al. | Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. | 2009 | Am. J. Gastroenterol. | pmid:19844205 |
| Ozmen MM and Johnson CD | Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? | 1995 | Am. J. Gastroenterol. | pmid:7661197 |
| Savarino V et al. | New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. | 1995 | Am. J. Gastroenterol. | pmid:7717343 |
| Zullo A et al. | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. | 1997 | Am. J. Gastroenterol. | pmid:9362185 |
| Moayyedi P and Malfertheiner P | Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? | 2009 | Am. J. Gastroenterol. | pmid:19956122 |
| Zullo A et al. | A quintuple therapy for H. pylori eradication. | 2007 | Am. J. Gastroenterol. | pmid:17958765 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| Calvet X et al. | Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. | 2005 | Am. J. Gastroenterol. | pmid:16086704 |
| Santander C et al. | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. | 1996 | Am. J. Gastroenterol. | pmid:8759659 |
| Tursi A et al. | Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. | 1996 | Am. J. Gastroenterol. | pmid:8759696 |
| Fuccio L et al. | Can sequential therapy for Helicobacter pylori eradication overcome clarithromycin resistance?: Data still do not support conclusions. | 2010 | Am. J. Gastroenterol. | pmid:20606668 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Laine L et al. | Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. | 2000 | Am. J. Gastroenterol. | pmid:11151867 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Nakao K et al. | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. | 1997 | Am. J. Gastroenterol. | pmid:9177520 |
| Maconi G et al. | Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 | Am. J. Gastroenterol. | pmid:11232676 |
| Nam SY et al. | Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. | 2010 | Am. J. Gastroenterol. | pmid:20571493 |
| Luther J et al. | Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. | 2010 | Am. J. Gastroenterol. | pmid:19755966 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |